<DOC>
	<DOCNO>NCT01169298</DOCNO>
	<brief_summary>To determine maximum tolerate dose lenalidomide patient adult T-cell leukemia-lymphoma ( ATL ) peripheral T-cell lymphoma ( PTCL ) previously receive therapy ATL PTCL</brief_summary>
	<brief_title>A Phase I , Multicenter , Open-label , Dose-escalation Study Assess Safety Lenalidomide Patients With Advanced Adult T-cell Leukemia-lymphoma Peripheral T-cell Lymphomaperipheral T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Subject must understand voluntarily sign write informed consent ; 2 . Aged 20 year old ; 3 . Subject documented diagnosis either : Acute , lymphoma , unfavorable chronictype ATL Peripheral Tcell Lymphomaperipheral ( PTCL ) 4 . Subject receive ≥1 prior anticancer therapy , achieve stable disease ( SD ) well immediately prior therapy relapse progressed time obtain sign informed consent ; 5 . Subject Eastern Cooperative Oncology Group performance status ( ECOG PS ) 0 2 enrollment ; 1 . Natural Killer cell lymphoma ( NKcell lymphoma ) ; 2 . Tcell leukemia ; 3 . Cutaneous Tcell lymphoma ( CTCL ) include ; Mycosis fungoides Sezary syndrome CD30positive lymphoproliferative disorder Cutaneous gamma/delta Tcell lymphoma 4 . Subject history central nervous system ( CNS ) involvement present CNS symptom , diagnose CNS lymphoma cerebrospinal fluid ( CSF ) cytology examination , head CT scan brain MRI screening ; 5 . Are pregnant lactating ; 6 . Subject uncontrolled intercurrent illness include : Uncontrolled diabetes mellitus Chronic congestive heart failure ( NYHA Class III IV ) Unstable angina pectoris , angioplasty , stenting , myocardial infarction ( within 6 month start study drug ) Clinically significant cardiac arrhythmia symptomatic require treatment , asymptomatic sustain ventricular tachycardia Other uncontrolled disease 7 . Exhibit grade 4 neurological disorder ; 8 . Subject history complication deep vein thrombosis pulmonary embolism within 6 month start study treatment ; 9 . Develop active tuberculous disease , herpes simplex , systemic mycosis , active infection require systemic administration antibiotic , antiviral agent , antifungal drug ; 10 . Are test positive HBs antigen , antiHCV antibody , antiHIV antibody ; 11 . Subjects history complication investigator subinvestigator deem inappropriate study , serious disease mental illness likely aggravate participation study ; 12 . Subjects history allogeneic stem cell transplantation ; 13 . Subjects receive autologous stem cell transplantation within 12 week ( 84 day ) start study treatment ; 14 . Have previously use lenalidomide ; 15 . Have history desquamating ( bullous ) rash take thalidomide ; 16 . Have receive investigational drug ( unapproved drug Japan ) within 4 week ( 28 day ) start study medication ; 17 . Have receive chemotherapeutic agent immunomodulators treatment ATL PTCL within 4 week ( 28 day ) start study treatment ; 18 . Have receive radiotherapy within 4 week ( 28 day ) start study treatment ; 19 . Have history complication another malignant tumor ATL PTCL ( exclude malignant tumor ) , unless patient free disease 5 year longer ; Cutaneous basal cell carcinoma squamous cell carcinoma Cervical carcinoma situ An incidental histological finding prostate carcinoma ( TNM stage T1a T1b ) 20 . Have follow abnormal measurement screen perform within 1 week ( 7 day ) prior enrollment ; Neutrophil count : &lt; 1,200/µL ( 1.2 x 109/L ) Platelet count : &lt; 75,000/µL ( 75 x 109/L ) Serum aspartate aminotransferase/ Serum glutamic oxaloacetic transaminase ( AST/SGOT ) Alanine transaminase/Serum Glutamic Pyruvate Transaminase ( ALT/SGPT ) : &gt; 3 time Upper Limit Normal ( ULN ) Bilirubin level : &gt; 1.5 time ULN Creatinine clearance : &lt; 60 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adult T-cell Leukemia-Lymphoma</keyword>
	<keyword>Peripheral T-cell Lymphoma</keyword>
	<keyword>PTCL</keyword>
	<keyword>HTLV-1</keyword>
</DOC>